Nathan Fowler - Concepedia

Author

Nathan Fowler

The University of Texas MD Anderson Cancer Center ORCID

Also Known As

N Fowler, N. Fowler, N. H. Fowler, N.H. Fowler, Nathan Fowler, Nathan H Fowler, Nathan H. Fowler, Nathan Hale Fowler, Sairah Ahmed

577

Publications

18K

Citations

H-Index

143

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center Cornell University Sarah Cannon University of California, Los Angeles Clearview Cancer Institute

About

Nathan Fowler is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, oncology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	35	75	7.6K
2	Health Sciences	19	30	1.9K
3	Engineering	2	2	135
4	Natural Sciences	1	1	71
5	Public Health	1	1	17

Nathan Fowler

180

Publications

15.5K

Citations

H-Index

Page 1

	Year	Citations
Conserved pan-cancer microenvironment subtypes predict response to immunotherapy Alexander Bagaev, Nikita Kotlov, Krystle Nomie, Cancer Cell Pan-cancer Microenvironment SubtypesCancer ImmunosurveillanceImmunologyImmune Checkpoint InhibitorImmunotherapy	2021	1.2K
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies Ranjana H. Advani, Joseph J. Buggy, Jeff P. Sharman, Journal of Clinical Oncology	2012	1.1K
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma Wyndham H. Wilson, Ryan M. Young, Roland Schmitz, Nature Medicine Lymphoid NeoplasiaMedicineImmunologyPathologyImmune Checkpoint Inhibitor	2015	1.1K
Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas Qing Deng, Guangchun Han, Nahum Puebla‐Osorio, Nature Medicine Lymphoid NeoplasiaRadiation OncologyCell TherapyCancer ImmunosurveillanceMedicine	2020	561
Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial Jason R. Westin, Fuliang Chu, Min Zhang, The Lancet Oncology Lymphoid NeoplasiaMedicineImmunologyPathologyImmune Checkpoint Inhibitor	2013	528
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial Nathan Fowler, Michael Dickinson, Martin Dreyling, Nature Medicine Lymphoid NeoplasiaHematologyImmunologyPathologyElara Trial	2021	492
Ibrutinib and Venetoclax for First-Line Treatment of CLL Nitin Jain, Michael J. Keating, Philip A. Thompson, New England Journal of Medicine	2019	491
AZD9150, a next-generation antisense oligonucleotide inhibitor of <i>STAT3</i> with early evidence of clinical activity in lymphoma and lung cancer David S. Hong, Razelle Kurzrock, Youngsoo Kim, Science Translational Medicine	2015	428
AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma John P. Leonard, Marek Trněný, Koji Izutsu, Journal of Clinical Oncology	2019	401
Double hit lymphoma: the <scp>MD A</scp> nderson <scp>C</scp> ancer <scp>C</scp> enter clinical experience Yasuhiro Oki, Mansoor Noorani, Pei Lin, British Journal of Haematology	2014	361

Page 1